Your browser doesn't support javascript.
loading
Medical Therapy of Aggressive Pituitary Tumors.
Petersenn, Stephan.
Affiliation
  • Petersenn S; ENDOC Center for Endocrine Tumors, Hamburg, Germany.
Exp Clin Endocrinol Diabetes ; 129(3): 186-193, 2021 Mar.
Article in En | MEDLINE | ID: mdl-33690871
ABSTRACT
The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas has been improved due to recent studies demonstrating clinically-relevant efficacy of temozolomide, which is now considered first-line chemotherapy. However, there is limited data on second-line therapies in patients with treatment failure. This review presents a summary on the potential of medical therapies in aggressive pituitary tumors.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Enzyme Inhibitors / Bevacizumab / Temozolomide / Immune Checkpoint Inhibitors / Antineoplastic Agents Limits: Humans Language: En Journal: Exp Clin Endocrinol Diabetes Journal subject: ENDOCRINOLOGIA Year: 2021 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Enzyme Inhibitors / Bevacizumab / Temozolomide / Immune Checkpoint Inhibitors / Antineoplastic Agents Limits: Humans Language: En Journal: Exp Clin Endocrinol Diabetes Journal subject: ENDOCRINOLOGIA Year: 2021 Document type: Article Affiliation country: Alemania